文献速递胸部肿瘤

新辅助程序性细胞死亡蛋白-1抑制剂(信迪利单抗)治疗非小细胞肺癌的三年随访

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC.
PubMed 文献 · J Thorac Oncol · 2022-05-10

这项1b期研究对IA至IIIB期非小细胞肺癌患者给予两剂信迪利单抗200mg静脉注射后手术,平均随访37.8个月,R0切除患者3年总生存率88.5%、无病生存率75.0%,PD-L1阳性患者3年总生存率和无病生存率分别为95.5%和81.8%。

要点

  • IA至IIIB期NSCLC患者接受两剂信迪利单抗200mg新辅助治疗后手术,平均随访37.8个月。
  • R0切除患者3年OS率88.5%,3年DFS率75.0%;PD-L1阳性患者3年OS和DFS分别为95.5%和81.8%。
  • PD-L1≥1%患者临床结局优于其他亚组(HR=0.275,95%CI 0.078-0.976)。

核心结论

  • 这是首个报告NSCLC患者接受PD-1抑制剂新辅助治疗长期生存概率的研究。
  • 3年随访结果显示PD-L1阳性且高肿瘤突变负荷患者临床结局良好。

研究设计与样本

  • 1b期研究,纳入IA至IIIB期NSCLC患者,给予两剂信迪利单抗200mg静脉注射,首次给药后29至43天内手术(注册号ChiCTR-OIC-17013726)。
  • 所有患者在入组时和术前接受PET-CT评估肿瘤代谢,并对32例合格患者进行PD-L1表达探索性分析。
  • 主要终点为安全性,关键次要终点包括总生存期、无病生存期、无事件生存期和主要病理缓解。

主要发现

  • 平均随访37.8个月,R0切除患者3年OS率为88.5%,3年DFS率为75.0%。
  • PD-L1阳性患者3年OS率和DFS率分别为95.5%和81.8%。
  • 8例患者出现肿瘤复发,包括局部复发、肺转移、脑转移和骨转移。
  • PD-L1≥1%患者临床结局优于其他亚组(HR=0.275,95%CI 0.078-0.976)。
  • 3年随访期间未出现新的不良事件,因首次报告已于前期发表。

关键数值与推荐

  • 信迪利单抗200mg静脉注射,共两剂。
  • 首次给药后29至43天内进行手术。
  • PD-L1≥1%患者对比其他亚组的HR=0.275(95%CI 0.078-0.976)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Programmed cell death protein-1 (PD-1) inhibitors have been proved to be feasible and to have efficacy in multiple cancers, including NSCLC. But few studies have evaluated the effectiveness of PD-1 inhibitor as neoadjuvant therapy with a long-term follow-up. Here, in this phase 1b study with a 3-year follow-up, we reported the clinical outcomes of patients who received the PD-1 inhibitor as neoadjuvant therapy. METHODS: Two doses of sintilimab (intravenously, 200 mg) were used for patients with stages IA to IIIB NSCLC (registration number: ChiCTR-OIC-17013726). Then, surgery was performed within 29 to 43 days after the first dose. All patients underwent positron emission tomography-computed tomography at enrolment and before surgery to evaluate tumor metabolism after administration of PD-1 inhibitor. We also evaluated the expression of programmed death-ligand 1 (PD-L1) as an exploratory analysis in 32 eligible patients. Safety was the primary end point. Overall survival (OS), disease-free survival (DFS), event-free survival, and major pathologic response were the key secondary end points. RESULTS: With the mean follow-up of 37.8 months, 3-year OS rate was 88.5% and the 3-year DFS rate was 75.0% among patients who underwent R0 resection. In patients with positive PD-L1 expression, 3-year OS and DFS rates were 95.5% and 81.8%, respectively. Eight patients had recurrent tumors, including local recurrence, lung metastasis, brain metastasis, and bone metastasis. Patients with PD-L1 greater than or equal to 1% had more favorable clinical outcomes than the other subgroup (hazard ratio = 0.275, 95% confidence interval: 0.078-0.976). No more new adverse events have occurred in the 3-year follow-up because we first reported them in the former publication. CONCLUSIONS: This is the first study to report the long-term survival probability of patients with NSCLC receiving PD-1 inhibitors as the neoadjuvant treatment. The 3-year follow-up results revealed that patients with positive PD-L1 expression and high tumor mutation burden have favorable clinical outcomes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang F, Guo W, Zhou B, et al. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022. PMID: 35550174. doi:10.1016/j.jtho.2022.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。